{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:09:40Z","timestamp":1775236180300,"version":"3.50.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.ijantimicag.2011.03.004","type":"journal-article","created":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T12:02:21Z","timestamp":1304942541000},"page":"118-124","source":"Crossref","is-referenced-by-count":36,"title":["Antiprotozoal compounds: state of the art and new developments"],"prefix":"10.1016","volume":"38","author":[{"given":"F.","family":"Astelbauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Walochnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0005","series-title":"World malaria report 2009","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0010","first-page":"83","article-title":"Parasitological and serological surveys for malaria among the inhabitants of an aborigine village and an adjacent Malay village","volume":"44","author":"Mak","year":"1987","journal-title":"Acta Trop"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0015","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0140-6736(04)15836-4","article-title":"A large focus of naturally acquired Plasmodium knowlesi infections in human beings","volume":"363","author":"Singh","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0020","series-title":"Essential malariology","author":"Warrel","year":"2002"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0025","series-title":"The history of malaria, an ancient disease","author":"US Centers for Disease Control and Prevention","year":"2004"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0030","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(05)66420-3","article-title":"Malaria","volume":"365","author":"Greenwood","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/pgmj.2004.030304","article-title":"Malaria in the post-genomics era: light at the end of the tunnel or just another train?","volume":"81","author":"Gardiner","year":"2005","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1201-9712(99)90010-3","article-title":"Drug development output from 1975 to 1996: what proportion for tropical diseases?","volume":"3","author":"Trouiller","year":"1998","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.pharmthera.2007.03.016","article-title":"In search of cyclooxygenase inhibitors, anti-Mycobacterium tuberculosis and anti-malarial drugs from Thai flora and microbes","volume":"115","author":"Gale","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0050","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1056\/NEJMc0805011","article-title":"Evidence of artemisinin-resistant malaria in western Cambodia","volume":"359","author":"Noedl","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0055","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJMc0900231","article-title":"Artemisinin-resistant malaria in Asia","volume":"361","author":"Noedl","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0060","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3184\/003685009X440290","article-title":"Eradicating malaria","volume":"92","author":"Breman","year":"2009","journal-title":"Sci Prog"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0070","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S1471-4922(02)02353-X","article-title":"Breaking down the blood\u2013brain barrier: signaling a path to cerebral malaria?","volume":"18","author":"Adams","year":"2002","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0075","series-title":"Guidelines for the treatment of malaria","author":"World Health Organization","year":"2010"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0080","series-title":"Guidelines for treatment of malaria in the United States","author":"US Centers for Disease Control and Prevention","year":"2009"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0085","unstructured":"Pfizer pipeline as of September 27, 2010. Groton, CT: Pfizer Inc., CT; 2010. http:\/\/media.pfizer.com\/files\/research\/pipeline\/2010_0927\/pipeline_2010_0927.pdf [accessed 23 March 2011]."},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/1475-2875-7-255","article-title":"Azithromycin\u2013chloroquine and the intermittent preventive treatment of malaria in pregnancy","volume":"7","author":"Chico","year":"2008","journal-title":"Malar J"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0095","unstructured":"Pfizer and Medicines for Malaria Venture seek to expand fight against malaria with intermittent preventive treatment option for pregnant women. Geneva, Switzerland: Medicines for Malaria Venture; 2010. http:\/\/www.mmv.org\/sites\/default\/files\/uploads\/docs\/press_releases\/Pfizer_and_MMV.pdf [accessed 23 March 2011]."},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0100","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(65)90395-8","article-title":"Chloroquine-resistant falciparum malaria in Thailand","volume":"2","author":"Harinasuta","year":"1965","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0105","series-title":"Malaria in the Greater Mekong subregion: regional and country profiles","author":"World Health Organization","year":"2008"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0110","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3201\/eid1405.071601","article-title":"Declining artesunate\u2013mefloquine efficacy against falciparum malaria on the Cambodia\u2013Thailand border","volume":"14","author":"Wongsrichanalai","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0115","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/415686a","article-title":"scientific opportunity and the drive for antimalarial drugs","volume":"415","author":"Ridley","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0120","series-title":"Harrison's principles of internal medicine","first-page":"1280","article-title":"Malaria","author":"White","year":"2008"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00002018-199614030-00001","article-title":"The safety of antimalarial drugs in pregnancy","volume":"14","author":"Phillips-Howard","year":"1996","journal-title":"Drug Saf"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1708-8305.1998.tb00484.x","article-title":"Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy","volume":"5","author":"Phillips-Howard","year":"1998","journal-title":"J Travel Med"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0135","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1128\/AAC.00777-06","article-title":"In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti","volume":"50","author":"Pradines","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0140","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/AAC.00354-09","article-title":"Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects","volume":"54","author":"Nasveld","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0145","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1126\/science.1193225","article-title":"Spiroindolones, a potent compound class for the treatment of malaria","volume":"329","author":"Rottmann","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0150","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1021\/jm100410f","article-title":"Spirotetrahydro \u03b2-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria","volume":"53","author":"Yeung","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0155","series-title":"Research and development portfolio","author":"Medicines for Malaria Venture","year":"2010"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0160","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.4269\/ajtmh.1982.31.1291","article-title":"Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection","volume":"31","author":"Krotoski","year":"1982","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0165","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/302424a0","article-title":"Malaria parasites\u2014discovery of the early liver form","volume":"302","author":"Meis","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0170","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.1982.31.24","article-title":"Observations on early and late post-sporozoite tissue stages in primate malaria I. Discovery of a new latent form of Plasmodium cynomolgi (the hypnozoite), and failure to detect hepatic forms within the first 24hours after infection","volume":"31","author":"Krotoski","year":"1982","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0175","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0035-9203(90)90003-W","article-title":"Efficacy of amodiaquine against a chloroquine-resistant strain of Plasmodium vivax","volume":"84","author":"Cooper","year":"1990","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0180","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.44.6.1680-1685.2000","article-title":"Therapeutic responses to different antimalarial drugs in vivax malaria","volume":"44","author":"Pukrittayakamee","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0185","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4269\/ajtmh.2001.64.223","article-title":"Chloroquine\/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia","volume":"64","author":"Taylor","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0190","series-title":"The use of antimalarial drugs. Report of an informal consultation","author":"World Health Organization","year":"2001"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0195","doi-asserted-by":"crossref","first-page":"494","DOI":"10.4269\/ajtmh.2007.76.494","article-title":"Tafenoquine for the treatment of recurrent Plasmodium vivax malaria","volume":"76","author":"Kitchener","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0140-6736(03)15230-0","article-title":"Drug combinations for malaria: time to ACT?","volume":"363","author":"Duffy","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0205","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0035-9203(01)90160-9","article-title":"Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India","volume":"95","author":"Thakur","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0166-6851(94)90095-7","article-title":"High level arsenite resistance in Leishmania tarentolae is mediated by an active extrusion system","volume":"67","author":"Dey","year":"1994","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0215","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1074\/jbc.M005423200","article-title":"Novel intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani","volume":"276","author":"Shaked-Mishan","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0220","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1128\/AAC.42.7.1689","article-title":"Gene amplification in Leishmania tarentolae selected for resistance to sodium stibogluconate","volume":"42","author":"Haimeur","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0225","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1590\/S0037-86822000000400009","article-title":"Comparative study between sodium stibogluconate BP 88 and meglumine antimoniate in cutaneous leishmaniasis treatment II. Biochemical and cardiac toxicity","volume":"33","author":"Saldanha","year":"2000","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0230","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0035-9203(03)80043-3","article-title":"Sodium stibogluconate cardiotoxicity and safety of generics","volume":"97","author":"Rijal","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0235","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4269\/ajtmh.1999.61.766","article-title":"High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients","volume":"61","author":"Delgado","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0240","series-title":"Drugs for parasitic infections","author":"US Centers for Disease Control and Prevention","year":"2010"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0245","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1051\/parasite\/2000072103","article-title":"In vivo antileishmanial action of Ir-(COD)-pentamidine tetraphenylborate on Leishmania donovani and Leishmania major mouse models","volume":"7","author":"Loiseau","year":"2000","journal-title":"Parasite"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0250","first-page":"171","article-title":"Pharmacologic aspects of pentamidine","volume":"43","author":"Waalkes","year":"1976","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0255","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1128\/CMR.9.4.512","article-title":"Carrier effects on biological activity of amphotericin B","volume":"9","author":"Brajtburg","year":"1996","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0260","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jac\/44.1.71","article-title":"Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis","volume":"44","author":"Di Giorgio","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0265","unstructured":"AmBisome. Astellas Pharma US; 2010. http:\/\/www.ambisome.com\/index2.php?section=about&page=overview [accessed 23 March 2011]."},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0270","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/507530","article-title":"Liposomal amphotericin B for the treatment of visceral leishmaniasis","volume":"43","author":"Bern","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0275","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/515085","article-title":"U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis","volume":"28","author":"Meyerhoff","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0280","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0285","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1473-3099(05)70296-6","article-title":"Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980\u20132004","volume":"5","author":"Olliaro","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0290","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0924-8579(03)00125-0","article-title":"Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine)","volume":"22","author":"Seifert","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0295","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1128\/AAC.47.8.2397-2403.2003","article-title":"Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug","volume":"47","author":"Perez-Victoria","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0300","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/14787210.4.2.177","article-title":"Miltefosine: oral treatment of leishmaniasis","volume":"4","author":"Soto","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0305","first-page":"623","article-title":"Current status and perspectives of the immunotherapy of leishmaniasis","volume":"11","author":"El-On","year":"2009","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0310","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1128\/AAC.43.12.2910","article-title":"Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases","volume":"43","author":"Al-Abdely","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0315","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1128\/AAC.00498-10","article-title":"Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system African trypanosomiasis","volume":"54","author":"Nare","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0320","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1128\/AAC.00985-10","article-title":"Antileishmanial and antitrypanosomal activities of the 8-aminoquinoline tafenoquine","volume":"54","author":"Yardley","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0325","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijantimicag.2010.03.008","article-title":"Efficacy of artemisinin in experimental visceral leishmaniasis","volume":"36","author":"Sen","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0330","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1590\/S0074-02762002000100001","article-title":"A critical review on Chagas disease chemotherapy","volume":"97","author":"Rodriques Coura","year":"2002","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0335","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1365-3156.2000.00548.x","article-title":"Congenital transmission of Trypanosoma cruzi: an operational outline for detecting and treating infected infants in north-western Argentina","volume":"5","author":"Blanco","year":"2000","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0340","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1590\/S0037-86822009000500002","article-title":"Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission","volume":"42","author":"Sosa-Estani","year":"2009","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0345","series-title":"Update of American trypanosomiasis and leishmaniasis control and research: final report","author":"World Health Organization","year":"2007"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0350","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0002-8703(94)90521-5","article-title":"Treatment of chronic Chagas\u2019 disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up","volume":"127","author":"Viotti","year":"1994","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0355","first-page":"1219","article-title":"Differential effect of amphotericin B on the three evolutive stages of Trypanosoma cruzi and on the host cell\u2013parasite interaction","volume":"26","author":"de-Castro","year":"1993","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0360","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4269\/ajtmh.1980.29.761","article-title":"Prevention of transfusion-induced Chagas\u2019 disease by amphotericin B","volume":"29","author":"Cruz","year":"1980","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0365","unstructured":"Bioral\u00ae amphotericin B. Raleigh, NC: BioDelivery Sciences International, Inc.; 2010. http:\/\/www.biodeliverysciences.com\/Bioral_Amphotericin_B.php [accessed 23 March 2011]."},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0370","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4269\/ajtmh.2010.09-0620","article-title":"Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus","volume":"82","author":"Pinazo","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0375","series-title":"Press release: Eisai and DNDi enter into a collaboration and license agreement to develop a new drug for Chagas disease","author":"DNDi","year":"2009"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0380","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.1371\/journal.pntd.0000923","article-title":"Fexinidazole\u2014a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness","volume":"4","author":"Torreele","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0385","unstructured":"Al-Saffer R, Ridge AL. Overview of the evidence for safety and efficacy of medicines for the treatment of neglected tropical diseases in children. WHO Documents 2010. https:\/\/www.who.int\/selection_medicines\/committees\/expert\/18\/applications\/ReviewNTDMedicines.pdf [accessed 23 March 2011]."},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0390","first-page":"11","article-title":"Treatment of vaginal infections with intravaginal pentamycin in clinical practice","author":"Balmer","year":"2009","journal-title":"Internat J Gynecol Obstet"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0395","first-page":"CD006085","article-title":"Antiamoebic drugs for treating amoebic colitis","author":"Gonzales","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0400","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/187152610791591610","article-title":"Giardiasis in the post genomic era: treatment, drug resistance and novel therapeutic perspectives","volume":"10","author":"Lalle","year":"2010","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0405","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1586\/14787210.5.5.893","article-title":"Invasive amebiasis: an update on diagnosis and management","volume":"5","author":"Salles","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0410","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/OLQ.0b013e3181cfcd8c","article-title":"Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population","volume":"37","author":"Krashin","year":"2010","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.ijantimicag.2011.03.004_bib0415","first-page":"115","article-title":"Drug resistance in amoebiasis","volume":"123","author":"Bansal","year":"2006","journal-title":"Indian J Med Res"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857911001476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857911001476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T23:19:49Z","timestamp":1637623189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857911001476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0924857911001476"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.03.004","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}